There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on X4 Pharmaceuticals (XFOR – Research Report), MiNK Therapeutics (INKT – Research Report) and Vigil Neuroscience Inc (VIGL – Research Report) with bullish sentiments.
X4 Pharmaceuticals (XFOR)
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on X4 Pharmaceuticals today and set a price target of $3.00. The company’s shares closed last Tuesday at $0.90, close to its 52-week low of $0.65.
According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on X4 Pharmaceuticals is a Moderate Buy with an average price target of $4.25, a 388.6% upside from current levels. In a report released yesterday, Brookline Capital Markets also maintained a Buy rating on the stock with a $4.50 price target.
See today’s best-performing stocks on TipRanks >>
MiNK Therapeutics (INKT)
In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on MiNK Therapeutics, with a price target of $7.00. The company’s shares closed last Tuesday at $2.04.
According to TipRanks.com, Bodnar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The the analyst consensus on MiNK Therapeutics is currently a Hold rating.
Vigil Neuroscience Inc (VIGL)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Vigil Neuroscience Inc, with a price target of $24.00. The company’s shares closed last Tuesday at $9.80.
According to TipRanks.com, Fein has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Vigil Neuroscience Inc.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on XFOR:
- X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
- X4 Pharmaceuticals says held about 2.5% of cash deposits at SVB
- X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2022 Financial Results and Host a Conference Call and Webcast on March 21, 2023
- X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
